DJIA 16,208.17 149.82 0.93%
NASDAQ 4,683.50 47.40 1.02%
S&P 500 1,931.22 17.37 0.91%
market minute promo

Isis Pharmaceuticals (NASDAQ: ISIS)

50.40 1.65 (3.38%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

ISIS $50.40 3.38%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $49.05
Previous Close $48.75
Daily Range $48.65 - $50.74
52-Week Range $35.26 - $77.80
Market Cap $6.0B
P/E Ratio 256.58
Dividend (Yield) $0.00 (0.0%)
Volume 633,525
Average Daily Volume 1,750,931
Current FY EPS -$0.52

Sector

Healthcare

Industry

Drug Makers

Isis Pharmaceuticals (ISIS) Description

The Company is a biopharmaceutical company exploiting proprietary RNA-based drug discovery technologies to create a new class of drugs to treat important diseases. Website: http://www.isispharm.com/

News & Commentary

Isis' News-Filled Week

The biotech announces a new partnership, clinical trial results, and earnings over the course of two days.

5 Top BioPharma Stocks That May Have Sold Off Too Much and Become Bargains

3 Promising Biotechs Hobbled By First-Impression Issues

Isis Pharmaceuticals Enters Oversold Territory (ISIS)

Isis Pharmaceuticals Misses on Q2 Earnings and Revenues - Analyst Blog

Isis Pharmaceuticals Misses on Q2 Earnings and Revenues - Analyst Blog

Isis Pharmaceuticals (ISIS) Earnings Report: Q2 2015 Conference Call Transcript

Isis Pharmaceuticals' (ISIS) CEO Stan Crooke on Q2 2015 Results - Earnings Call Transcript

Isis Pharmaceuticals (ISIS) Misses Earnings Estimates in Q2 - Tale of the Tape

Will Isis Pharmaceuticals (ISIS) Beat Q2 Earnings Estimates? - Analyst Blog

Isis Pharma 8-K Filing Shows Company Enters Agreement with Astrazeneca To Discover And Develop Antis

Isis Pharma 8-K Filing Shows Company Enters Agreement with Astrazeneca To Discover And Develop Antisense Drugs FOr Cardiovascular, Metabolic And Renal Disease

See More ISIS News...

ISIS's Top Competitors

ISIS $50.40 (3.38%)
Current stock: ISIS
AMGN $148.21 (0.51%)
Current stock: AMGN
GILD $102.05 (0.55%)
Current stock: GILD
BIIB $299.77 (2.49%)
Current stock: BIIB